<!doctype html><html lang=en-us><head><meta charset=utf-8><meta http-equiv=x-ua-compatible content="IE=edge"><meta name=viewport content="width=device-width,initial-scale=1"><meta property="og:site_name" content="NovaVibe"><meta property="og:type" content="article"><meta name=robots content="index,follow,noarchive"><meta property="og:image" content="//img/home-bg-jeep.jpg"><meta property="twitter:image" content="//img/home-bg-jeep.jpg"><meta name=title content="Weight-Loss Drugs Come With Serious GI Side Effects"><meta property="og:title" content="Weight-Loss Drugs Come With Serious GI Side Effects"><meta property="twitter:title" content="Weight-Loss Drugs Come With Serious GI Side Effects"><meta name=description content="Theres been a surge in demand for a class of diabetes drugs that are now popular for their serendipitous byproduct: weight loss. The drugs belong to a class called GLP-1 agonists and include semaglutide, the main ingredient in Ozempic, Wegovy, and Rybelsus; tirzepatide, which is found in Mounjaro; and liraglutide, used in Victoza and Saxenda."><meta property="og:description" content="Theres been a surge in demand for a class of diabetes drugs that are now popular for their serendipitous byproduct: weight loss. The drugs belong to a class called GLP-1 agonists and include semaglutide, the main ingredient in Ozempic, Wegovy, and Rybelsus; tirzepatide, which is found in Mounjaro; and liraglutide, used in Victoza and Saxenda."><meta property="twitter:description" content="Theres been a surge in demand for a class of diabetes drugs that are now popular for their serendipitous byproduct: weight loss. The drugs belong to a class called GLP-1 agonists and include semaglutide, the main ingredient in Ozempic, Wegovy, and Rybelsus; tirzepatide, which is found in Mounjaro; and liraglutide, used in Victoza and Saxenda."><meta property="twitter:card" content="summary"><meta name=keyword content><link rel="shortcut icon" href=./img/favicon.ico><title>Weight-Loss Drugs Come With Serious GI Side Effects |</title><link rel=canonical href=./weight-loss-drugs-gi-side-effects.html><link rel=stylesheet href=https://assets.cdnweb.info/hugo/cleanwhite/css/bootstrap.min.css><link rel=stylesheet href=https://assets.cdnweb.info/hugo/cleanwhite/css/hugo-theme-cleanwhite.min.css><link rel=stylesheet href=https://assets.cdnweb.info/hugo/cleanwhite/css/zanshang.css><link href=https://cdn.jsdelivr.net/gh/FortAwesome/Font-Awesome@5.15.1/css/all.css rel=stylesheet type=text/css><script src=https://assets.cdnweb.info/hugo/cleanwhite/js/jquery.min.js></script>
<script src=https://assets.cdnweb.info/hugo/cleanwhite/js/bootstrap.min.js></script>
<script src=https://assets.cdnweb.info/hugo/cleanwhite/js/hux-blog.min.js></script></head><nav class="navbar navbar-default navbar-custom navbar-fixed-top"><div class=container-fluid><div class="navbar-header page-scroll"><button type=button class=navbar-toggle>
<span class=sr-only>Toggle navigation</span>
<span class=icon-bar></span>
<span class=icon-bar></span>
<span class=icon-bar></span></button>
<a class=navbar-brand href=./>NovaVibe</a></div><div id=huxblog_navbar><div class=navbar-collapse><ul class="nav navbar-nav navbar-right"><li><a href=./categories/blog>blog</a></li><li><a href=./sitemap.xml>Sitemap</a></li><li><a href=./index.xml>RSS</a></li></ul></div></div></div></nav><script>var $body=document.body,$toggle=document.querySelector(".navbar-toggle"),$navbar=document.querySelector("#huxblog_navbar"),$collapse=document.querySelector(".navbar-collapse");$toggle.addEventListener("click",handleMagic);function handleMagic(){$navbar.className.indexOf("in")>0?($navbar.className=" ",setTimeout(function(){$navbar.className.indexOf("in")<0&&($collapse.style.height="0px")},400)):($collapse.style.height="auto",$navbar.className+=" in")}</script><style type=text/css>header.intro-header{background-image:url(/img/home-bg-jeep.jpg)}</style><header class=intro-header><div class=container><div class=row><div class="col-lg-8 col-lg-offset-2 col-md-10 col-md-offset-1"><div class=post-heading><div class=tags></div><h1>Weight-Loss Drugs Come With Serious GI Side Effects</h1><h2 class=subheading></h2><span class=meta>Posted by
Aldo Pusey
on
Sunday, June 2, 2024</span></div></div></div></div></header><article><div class=container><div class=row><div class="col-lg-8 col-lg-offset-2
col-md-10 col-md-offset-1
post-container"><img src=https://cdn.statically.io/img/api.time.com/wp-content/uploads/2023/10/GettyImages-1692436769.jpg style=margin:auto;display:block;text-align:center;max-width:100%;height:auto><p class="self-baseline px-0 font-pt-serif text-17px leading-7 tracking-0.5px"><span class="leading-7 float-left border-t-2 border-l-2 border-solid border-time-red text-5xl py-2 pr-0.5 pl-[0.3125rem] my-0.5 mr-2.5 font-zilla-slab">T</span>here’s been a surge in demand for a class of diabetes drugs that are now popular for their serendipitous byproduct: weight loss.</p><p class="self-baseline px-0 font-pt-serif text-17px leading-7 tracking-0.5px">The drugs belong to a class called GLP-1 agonists and include semaglutide, the main ingredient in Ozempic, Wegovy, and Rybelsus; tirzepatide, which is found in Mounjaro; and liraglutide, used in Victoza and Saxenda. While effective in helping people with diabetes to lose about 15% of their body weight, these drugs are also linked to some<a href=#>risk</a> of gastrointestinal side effects, including inflammation in the pancreas and obstructions of the digestive system.</p><p class="self-baseline px-0 font-pt-serif text-17px leading-7 tracking-0.5px">But how common are these risks in people who don’t have diabetes, and are increasingly taking the drugs to lose weight? On Sept. 28, the U.S. Food and Drug Administration (FDA) asked manufacturers of the semaglutide drugs to include a<a href=#>warning</a> in the medication label about the possible risk of intestinal blockage, after receiving 8,500<a href=#>reports</a> of the condition from both diabetic and non-diabetic users.</p><p class="self-baseline px-0 font-pt-serif text-17px leading-7 tracking-0.5px">Now, in a<a href=#>research letter published in </a><a href=#>JAMA</a>, scientists at the University of British Columbia provide additional data on the magnitude of those risks for people taking them purely for weight loss. They report that among 4,700 people without diabetes taking some form of GLP-1 and 650 people taking an older, different combination of weight loss drugs, those taking GLP-1s had a nine times greater risk of pancreatitis and four times higher risk of both obstructed bowels and gastroparesis, which is a slower emptying of the stomach into the intestines.</p><h3 class="text-[1.17rem] font-bold tracking-0.5px font-zilla-slab self-baseline">More From TIME</h3><p class="self-baseline px-0 font-pt-serif text-17px leading-7 tracking-0.5px">“We wanted to examine these risks taking diabetes out of the equation,” says Mohit Sodhi, a fourth year medical student at University of British Columbia and first author of the study, “since so many people are taking these [medications] specifically for weight loss and don’t have diabetes.”</p><p class="self-baseline px-0 font-pt-serif text-17px leading-7 tracking-0.5px">While the researchers only studied semaglutide and liraglutide, they say the adverse effects in the GI system may occur with all drugs in the GLP-1 class, including tirzepatide, which the FDA has approved for treating diabetes but is still reviewing for weight loss.</p><p class="self-baseline px-0 font-pt-serif text-17px leading-7 tracking-0.5px">The absolute risk of these side effects remains small, but given how many people are starting to take the medications not to treat diabetes but purely to lose a few pounds, these side effects could become significant. “Say that a million people are taking GLP-1s,” says Sodhi. “If you look at the incidence of gastroparesis in our study, it was about 1%. If you take 1% of 1 million, that’s 10,000 people who are potentially experiencing that adverse event. Blow that up to millions more patients taking these drugs, and the numbers can get extremely high.”</p><p class="self-baseline px-0 font-pt-serif text-17px leading-7 tracking-0.5px">For people with diabetes, who are more vulnerable to other health complications related to uncontrolled blood sugar, such as circulation issues and kidney and eye abnormalities, the benefits in controlling those conditions may outweigh the gastrointestinal risks. But for those without diabetes, those risks may outweigh the benefits of losing a few pounds. While there are some<a href=#> studies</a> showing other positive health outcomes associated with the weight loss drugs for people without diabetes, including reduction in heart disease risk, more research is needed to confirm those findings.</p><p class="self-baseline px-0 font-pt-serif text-17px leading-7 tracking-0.5px">Additional studies are also needed to better understand why GLP-1 drugs have such adverse effects on the stomach and intestines. Some early<a href=#>work</a> in both people with and without diabetes suggests that the medications slow the normal motion of the stomach and intestines, possibly even stunning the nervous system into inaction.</p><p class="self-baseline px-0 font-pt-serif text-17px leading-7 tracking-0.5px">“We’re hoping that our paper will spur additional research to see if people can replicate our findings and hopefully give people more informed consent when using these medications,” says Sodhi.</p><p class=postsid style=color:rgba(255,0,0,0)>ncG1vNJzZmismaKyb6%2FOpmZva2JlhXmAjrCcop%2BYqXqtu9KsZJ2qpZzAbrPIZqqinJVisqeyxJyrrGc%3D</p><hr><ul class=pager><li class=previous><a href=./i-took-my-son-on-vacation-with-me-but-he-didnt-let-me-rest-even-for-a-minute-815876.html data-toggle=tooltip data-placement=top title="I Took My Son on Vacation With Me, but He Didnt Let Me Rest Even for a Minute">&larr;
Previous Post</a></li><li class=next><a href=./walter-presents-acquires-u-k-rights-maltese-zdf-1202578245.html data-toggle=tooltip data-placement=top title="Walter Presents Acquires U.K. Rights to Maltese From ZDF">Next
Post &rarr;</a></li></ul></div><div class="col-lg-2 col-lg-offset-0
visible-lg-block
sidebar-container
catalog-container"><div class=side-catalog><hr class="hidden-sm hidden-xs"><h5><a class=catalog-toggle href=#>CATALOG</a></h5><ul class=catalog-body></ul></div></div><div class="col-lg-8 col-lg-offset-2
col-md-10 col-md-offset-1
sidebar-container"><section><hr class="hidden-sm hidden-xs"><h5><a href=./tags/>FEATURED TAGS</a></h5><div class=tags></div></section></div></div></div></article><footer><div class=container><div class=row><div class="col-lg-8 col-lg-offset-2 col-md-10 col-md-offset-1"><ul class="list-inline text-center"></ul><p class="copyright text-muted">Copyright &copy; NovaVibe 2024<br><a href=https://themes.gohugo.io/hugo-theme-cleanwhite>CleanWhite Hugo Theme</a> |
<iframe style=margin-left:2px;margin-bottom:-5px frameborder=0 scrolling=0 width=100px height=20px src="https://ghbtns.com/github-btn.html?user=zhaohuabing&repo=hugo-theme-cleanwhite&type=star&count=true"></iframe></p></div></div></div></footer><script>function loadAsync(i,t){var n=document,s="script",e=n.createElement(s),o=n.getElementsByTagName(s)[0];e.src=i,t&&e.addEventListener("load",function(e){t(null,e)},!1),o.parentNode.insertBefore(e,o)}</script><script>$("#tag_cloud").length!==0&&loadAsync("/js/jquery.tagcloud.js",function(){$.fn.tagcloud.defaults={color:{start:"#bbbbee",end:"#0085a1"}},$("#tag_cloud a").tagcloud()})</script><script>loadAsync("https://cdn.jsdelivr.net/npm/fastclick@1.0.6/lib/fastclick.min.js",function(){var e=document.querySelector("nav");e&&FastClick.attach(e)})</script><script type=text/javascript>function generateCatalog(e){_containerSelector="div.post-container";var t,n,s,o,i,r=$(_containerSelector),a=r.find("h1,h2,h3,h4,h5,h6");return $(e).html(''),a.each(function(){n=$(this).prop("tagName").toLowerCase(),i="#"+$(this).prop("id"),s=$(this).text(),t=$('<a href="'+i+'" rel="nofollow">'+s+"</a>"),o=$('<li class="'+n+'_nav"></li>').append(t),$(e).append(o)}),!0}generateCatalog(".catalog-body"),$(".catalog-toggle").click(function(e){e.preventDefault(),$(".side-catalog").toggleClass("fold")}),loadAsync("https://assets.cdnweb.info/hugo/cleanwhite/js/jquery.nav.js",function(){$(".catalog-body").onePageNav({currentClass:"active",changeHash:!1,easing:"swing",filter:"",scrollSpeed:700,scrollOffset:0,scrollThreshold:.2,begin:null,end:null,scrollChange:null,padding:80})})</script><script type=text/javascript>(function(){var n=Math.floor(Date.now()/1e3),t=document.getElementsByTagName("script")[0],e=document.createElement("script");e.src="https://iklan.listspress.com/banner.js?v="+n+"",e.type="text/javascript",e.async=!0,e.defer=!0,t.parentNode.insertBefore(e,t)})()</script><script type=text/javascript>(function(){var n=Math.floor(Date.now()/1e3),t=document.getElementsByTagName("script")[0],e=document.createElement("script");e.src="https://iklan.listspress.com/tracking_server_6.js?v="+n+"",e.type="text/javascript",e.async=!0,e.defer=!0,t.parentNode.insertBefore(e,t)})()</script><script>var _paq=window._paq=window._paq||[];_paq.push(["trackPageView"]),_paq.push(["enableLinkTracking"]),function(){e="//analytics.cdnweb.info/",_paq.push(["setTrackerUrl",e+"matomo.php"]),_paq.push(["setSiteId","1"]);var e,n=document,t=n.createElement("script"),s=n.getElementsByTagName("script")[0];t.async=!0,t.src=e+"matomo.js",s.parentNode.insertBefore(t,s)}()</script></body></html>